Females have the survival advantage in glioblastoma

Neuro-Oncology

Volumn 20, Issue 4, 2018, Pages 576-577

  Ostrom, Quinn T ^a   Rubin, Joshua B ^b   Lathia, Justin D ^c   Berens, Michael E ^d   Barnholtz Sloan, Jill S ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGE; CANCER REGISTRY; CANCER SURGERY; CHEMORADIOTHERAPY; DNA METHYLATION; FEMALE; GENE MUTATION; GLIOBLASTOMA; HUMAN; IDH1 GENE; IDH2 GENE; KARNOFSKY PERFORMANCE STATUS; LETTER; MALE; ONCOGENE; OVERALL SURVIVAL; SEX DIFFERENCE; TREATMENT RESPONSE; UNITED STATES; BRAIN TUMOR; FOLLOW UP; MORTALITY; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SEX FACTOR; SURVIVAL RATE;

BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; PROGNOSIS; SEER PROGRAM; SEX FACTORS; SURVIVAL RATE;

EID: 85045180936     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noy002     Document Type: Letter

References (7)

1. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 2017;19(suppl-5):v1-v88.
2. Stupp R, Mason W P, van den Bent MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glio-blastoma. N Engl J Med. 2005;352(10):987-996.
3. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer. cancer.gov) SEER∗Stat Database: Incidence-SEER 18 Regs Custom Data (with additional treatment felds), Nov 2016 Sub (2000-2014) Katrina/Rita Population Adjustment-Linked To County Attributes-Total U.S., 1969-2015 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2017, based on the November 2016 submission. 2017.
4. Ostrom QT, McCulloh C, Chen Y, et al. Family history of cancer in benign brain tumor subtypes versus gliomas. Front Oncol. 2012;2:19.
5. Ceccarelli M, Barthel F P, Malta TM, et al; TCGA Research Network. Molecular profling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550-563.
6. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
7. Schiffgens S, Wilkens L, Brandes AA, et al. Sex-specifc clinicopatho-logical signifcance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma. Oncotarget. 2016;7(34):55169-55180.